Advanced Oncotherapy PLC Update re admission of Subscription Shares (9667W)
August 23 2022 - 9:09AM
UK Regulatory
TIDMAVO
RNS Number : 9667W
Advanced Oncotherapy PLC
23 August 2022
23 August 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Update re admission of Subscription Shares
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment,
provides an update regarding the Subscription announced on 19
August 2022.
Admission, due to take place tomorrow, 24 August 2022, will now
comprise 4,460,000 Subscription Shares.
Application will be made for the remaining 1,400,000
Subscription Shares to be admitted to trading on AIM ("Second
Admission") and it is expected that Second Admission will occur on
or around 16 September 2022. The warrants relating to the
Subscription Shares being issued on Second Admission will be issued
on or around 17 September 2022.
Total Voting Rights
Following Admission on 24 August 2022, the Company's enlarged
issued share capital will comprise 505,831,209 Ordinary Shares, of
25 pence each ("Ordinary Shares"). The Company does not hold any
Ordinary Shares in treasury. Therefore, the total number of
Ordinary Shares in the Company with voting rights on 24 August 2022
will be 505,831,209 . Upon Second Admission, the Company's enlarged
issued share capital will comprise 507,231,209 Ordinary Shares, of
25 pence each and the total number of Ordinary Shares in the
Company with voting rights on Second Admission will be 507,231,209
. The aforementioned figures may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the announcement of 19 August 2022 unless otherwise
defined herein.
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR advancedoncotherapy@fticonsulting.com
& IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBKNBKQBKDFFB
(END) Dow Jones Newswires
August 23, 2022 10:09 ET (14:09 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024